AxioMx Inc., a Branford, Connecticut-based early-stage biotechnology company that offers a full range of custom antibody discovery and development services for the research, diagnostic and therapeutic marketplaces, completed a $2m second financing round.
Backers included Connecticut Innovations (CI), Elm Street Ventures, Vital Venture Capital and AxioMx company founders.
Founded in 2012 by Christopher McLeod, president and CEO, and and Dr. Michael Weiner, AxioMx is developing a novel, high-throughput method to synthetically generate affinity reagents, which are fragments of monoclonal antibodies that specifically bind to target proteins and are useful in life science research, diagnostic tests and as therapeutics.
The company’s antibodies are generated entirely in vitro which enables consistent antibody quality across production batches and does not involve the use of animals.
In the past nine months, customers have ordered over $750k of custom services including antigen design, novel antibody discovery and development, and affinity maturation of existing antibodies.
FinSMEs
08/10/2013
Related News
24/12/2012: AxioMx Raises $2.5M in Funding